Department of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Nephrology (Carlton). 2010 Aug;15(5):584-6. doi: 10.1111/j.1440-1797.2010.01278.x.
Immunoglobulin A nephropathy (IgAN), characterized by predominant or exclusive deposition of IgA1 in glomerular mesangium, is the most common primary glomerulonephritis worldwide. At present, the treatment is always limited due to the incomplete understanding of the pathogenesis of IgAN. Mesangial deposited IgA1 is the common final pathway leading to glomerulonephritis and renal injury. IgA1 protease, a proteolytic enzyme with strict substrate specificity for human IgA1, may be an effective therapeutic candidate for IgAN by removing the mesangial deposited IgA1.
免疫球蛋白 A 肾病（IgAN）的特征是 IgA1 主要或排他性地沉积在肾小球系膜中，是全球最常见的原发性肾小球肾炎。目前，由于对 IgAN 发病机制的不完全了解，治疗总是受到限制。沉积在系膜中的 IgA1 是导致肾小球肾炎和肾损伤的共同最终途径。IgA1 蛋白酶是一种对人 IgA1 具有严格底物特异性的蛋白水解酶，通过去除沉积在系膜中的 IgA1，可能成为 IgAN 的有效治疗候选药物。
